Condition: Melanoma · Sponsor: Shanghai Juncell Therapeutics
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
This description comes directly from the study's public registry record.
Jun Guo, Prof. Dr. Med · 86-10-88121122 · guoj307@126.com
Wei Shi · 86-21-69110327 · wei.shi1@juncell.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06703398